West Pharmaceutical Services, Inc. (NYSE:WST) Expected to Post Quarterly Sales of $614.77 Million

Share on StockTwits

Analysts expect that West Pharmaceutical Services, Inc. (NYSE:WST) will post sales of $614.77 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for West Pharmaceutical Services’ earnings, with the lowest sales estimate coming in at $612.72 million and the highest estimate coming in at $617.60 million. West Pharmaceutical Services posted sales of $491.50 million in the same quarter last year, which suggests a positive year-over-year growth rate of 25.1%. The business is scheduled to report its next earnings report before the market opens on Thursday, April 22nd.

On average, analysts expect that West Pharmaceutical Services will report full year sales of $2.55 billion for the current year, with estimates ranging from $2.52 billion to $2.60 billion. For the next financial year, analysts forecast that the firm will post sales of $2.73 billion, with estimates ranging from $2.63 billion to $2.84 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow West Pharmaceutical Services.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, February 18th. The medical instruments supplier reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.21. The business had revenue of $580.20 million for the quarter, compared to analyst estimates of $542.07 million. West Pharmaceutical Services had a return on equity of 19.01% and a net margin of 14.69%.

Separately, Zacks Investment Research lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Thursday, March 18th.

A number of institutional investors have recently added to or reduced their stakes in WST. FMR LLC lifted its position in West Pharmaceutical Services by 41.3% during the 1st quarter. FMR LLC now owns 794 shares of the medical instruments supplier’s stock worth $88,000 after acquiring an additional 232 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in West Pharmaceutical Services during the 3rd quarter worth approximately $1,276,000. Voloridge Investment Management LLC purchased a new stake in West Pharmaceutical Services during the 3rd quarter worth approximately $254,000. Rehmann Capital Advisory Group purchased a new stake in West Pharmaceutical Services during the 3rd quarter worth approximately $210,000. Finally, Paces Ferry Wealth Advisors LLC purchased a new stake in West Pharmaceutical Services during the 3rd quarter worth approximately $77,000. 92.55% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE WST traded up $2.96 during midday trading on Wednesday, hitting $316.79. The stock had a trading volume of 334,371 shares, compared to its average volume of 465,698. The company has a market capitalization of $23.39 billion, a price-to-earnings ratio of 83.59, a PEG ratio of 3.86 and a beta of 1.13. West Pharmaceutical Services has a 1-year low of $163.79 and a 1-year high of $317.19. The company has a quick ratio of 2.23, a current ratio of 2.96 and a debt-to-equity ratio of 0.16. The company has a fifty day moving average price of $282.36 and a 200 day moving average price of $285.06.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 5th. Investors of record on Wednesday, April 21st will be given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.21%. The ex-dividend date is Tuesday, April 20th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 20.99%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components.

Read More: Price Target

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.